Abstract:Major depressive disorder (MDD) is a serious mental disorder with unclear pathogenesis. ProBDNF is a precursor protein of brain derived neurotrophic factor (BDNF) expressed in the central nervous system and peripheral tissues. Previous studies showed that blood proBDNF levels in MDD were increased. However, the relationship between proBDNF/p75NTR and inflammatory cytokines in peripheral blood of MDD is unknown. The current study examined the expression of proBDNF and inflammatory markers in patients with major depression. Peripheral blood mononuclear cells (PBMCs) and serum were obtained from depressive patients (n = 32) and normal donors (n = 20). We examined the mRNA and protein expression of proBDNF/p75NTR/sortilin signaling pathway, as well as tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-10 (IL-10) in human PBMCs. The Enzyme-Linked Immunosorbent Assay (ELISA) levels of these factors in the sera were also examined. Furthermore, the correlations between each factor and severity of major depression were tested. Of biomarkers studies, we found that proBDNF, p75NTR and sortilin production were significantly increased in PBMCs from MDD patients compared with that from the normal donors. The upregulation of p75NTR in PBMCs was most obvious as determined by qPRC and Western blots. Interestingly, the expression of proBDNF/p75NTR/sortilin signaling pathway in PBMC could be reversed after therapeutic management. Inflammatory cytokines in PBMC from MDD patients were also increased. Consistently, ELISA showed that the levels of p75NTR, sortilin, IL-1β and IL-10 in the serum of major depression were also increased compared with normal donors, and positively correlated with the major depression scores. The levels of IL-1β and IL-10 were also positively correlated with the major depression scores. Intriguingly, the levels of sortilin was positively correlated with IL-1β. Further flow cytometry studies showed that the number of proBDNF and p75NTR positive CD4 + , CD8 + T cells and CD19 + B cells from MDD patients was increased and subsequently reversed after therapeutic management. The findings suggest that the upregulation of proBDNF/p75NTR/sortilin signaling pathway may relate to inflammatory markers in patients with major depression. Our data also suggest that proBDNF/p75NTR/sortilin signaling pathway may serve as biomarkers for MDD.

Elevated Plasma Levels of Mature Brain-Derived Neurotrophic Factor in Major Depressive Disorder Patients with Higher Suicidal Ideation

Increased Ratio of Mature BDNF to Precursor-Bdnf in Patients with Major Depressive Disorder with Severe Anhedonia.

Association of Anhedonia with Brain-Derived Neurotrophic Factor and Interleukin-10 in Major Depressive Disorder

Effects of Neuronavigation-Guided Rtms on Serum BDNF, TrkB and VGF Levels in Depressive Patients with Suicidal Ideation

Increased Plasma Levels of IL-6 Are Associated with Striatal Structural Atrophy in Major Depressive Disorder Patients with Anhedonia

Upregulation of proBDNF/p75NTR signaling in immune cells and its correlation with inflammatory markers in patients with major depression

Correlations Between Probdnf/p75ntr and Inflammatory Markers in Patients with Major Depression

Peripheral Blood BDNF-TrkB Signaling in First-Episode, Drug-Free Patients with Major Depressive Disorder and Schizophrenia.

The serum protein levels of the tPA–BDNF pathway are implicated in depression and antidepressant treatment

Plasma Brain-Derived Neurotrophic Factor (BDNF) Concentration and the BDNF Val66Met Polymorphism in Suicide: a Prospective Study in Patients with Depressive Disorder

Brain-derived neurotrophic factor (BDNF) - TrkB signaling in inflammation-related depression and potential therapeutic targets.

Analysis of blood mature BDNF and proBDNF in mood disorders with specific ELISA assays

The changes of tPA/PAI-1 system are associated with the ratio of BDNF/proBDNF in major depressive disorder and SSRIs antidepressant treatment

Blood Brain-Derived Neurotrophic Factor (BDNF) and Major Depression: Do We Have a Translational Perspective?

BDNF As a Biomarker in Diagnosis and Evaluation of Treatment for Schizophrenia and Depression.

Association between inflammatory cytokines and symptoms of major depressive disorder in adults

Cognitive functions and serum levels of brain-derived neurotrophic factor in patients with major depressive disorder

Association Between the Enriched Environment Level and Serum Brain-Derived Neurotrophic Factor (BDNF) in Patients with Major Depressive Disorder

Increased expression of ER stress, inflammasome activation, and mitochondrial biogenesis-related genes in peripheral blood mononuclear cells in major depressive disorder

The Level of Serum Brain-Derived Neurotrophic Factor is Associated with the Therapeutic Efficacy of Modified Electroconvulsive Therapy in Chinese Patients with Depression

Brain-derived neurotrophic factor levels across psychiatric disorders: A systemic review and network meta-analysis